Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Organic solvents as risk factor for autoimmune diseases: a systematic review and meta-analysis.
Birth outcomes of pregnancies fathered by men with multiple sclerosis.
Sleep Disorders and Multiple Sclerosis: A Clinical and Polysomnography Study.
MS related employment and disease modifying treatment in the German working population: 1994-2009.
JC-virus seroconversion in multiple sclerosis patients receiving natalizumab.
Validity and Reliability of a Persian Translation of the Minimal Assessment of Cognitive Function in Multiple Sclerosis (MACFIMS).
Neuroproteomics and microRNAs studies in multiple sclerosis: transforming research and clinical knowledge in biomarker research.
In vitro modeling of central nervous system myelination and remyelination.
Bayer Receives FDA Approval for BETACONNECT - First and Only Electronic Autoinjector in Relapsing-Remitting Multiple Sclerosis (RRMS) Treatment
Inflammation-mediated memory dysfunction and effects of a ketogenic diet in a murine model of multiple sclerosis.
Assessment of cerebral venous return by a novel plethysmography method.
Infectious causes of multiple sclerosis.
Safety, efficacy, and pharmacokinetics/pharmacodynamics of daclizumab (anti-CD25) in patients with adult T-cell leukemia/lymphoma.
Natalizumab in the treatment of rheumatoid arthritis in subjects receiving methotrexate
Lipoatrophy in patients with multiple sclerosis on glatiramer acetate.
Ocrelizumab in multiple sclerosis: risks and benefits.
Cerebrospinal fluid detection of interleukin-1beta in phase of remission predicts disease progression in multiple sclerosis.
Neurofilament light antibodies in serum reflect response to natalizumab treatment in multiple sclerosis.
Oligodendrocytes Enforce Immune Tolerance of the Uninfected Brain by Purging the Peripheral Repertoire of Autoreactive CD8(+) T Cells.
Correlates of Executive Functions in Multiple Sclerosis Based on Structural and Functional MR Imaging: Insights from a Multicenter Study.
Solitary sclerosis: Progressive neurological deficit from a spatially isolated demyelinating lesion: A further report.
Sublime Microglia: Expanding Roles for the Guardians of the CNS.
Novartis receives European Commission approval for Gilenya®, the first oral multiple sclerosis treatment for use in the EU
Microbial colonization influences early B-lineage development in the gut lamina propria.
Anti-phospholipid antibodies are associated with response to interferon-beta1a treatment in MS: results from a 3-year longitudinal study.

Pages